University of Southern California (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
128
Publications
2427
Citations
107490
i10-index
805
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Sorafenib in Advanced Hepatocellular Carcinoma | 2008 | 12784 |
EASL Clinical Practice Guidelines: Management of h... | 2018 | 11239 |
Atezolizumab plus Bevacizumab in Unresectable Hepa... | 2020 | 6779 |
BCLC strategy for prognosis prediction and treatme... | 2021 | 3877 |
Simplified criteria for the diagnosis of autoimmun... | 2008 | 1833 |
Ramucirumab after sorafenib in patients with advan... | 2019 | 1624 |
Guidelines for the diagnosis and management of int... | 2014 | 1515 |
Updated efficacy and safety data from IMbrave150: ... | 2021 | 1477 |
Tremelimumab plus Durvalumab in Unresectable Hepat... | 2022 | 1293 |
Blockade of interleukin 6 trans signaling suppress... | 2000 | 1284 |
Peter R. Galle is a researcher with 2427 publications and 107490 citations. They are affiliated with University of Southern California. Their research focuses on . With an h-index of 128, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Peter R. Galle and 250M+ other papers.
Citations per publication by year